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Abstract
Background: To summarize data on long-term ipsilateral local recurrence (LR) and breast cancer death rate (BCDR)
for patients with ductal carcinoma in situ (DCIS) who received different treatments.
Methods: Systematic review and study-level meta-analysis of prospective (n = 5) and retrospective (n = 21) studies
of patients with pure DCIS and with median or mean follow-up time of ≥10 years. Meta-regression was performed
to assess and adjust for effects of potential confounders – the average age of women, period of initial treatment,
and of bias – follow-up duration on recurrence- and death-rates in each treatment group. LR and BCDR rates by
local treatment used were reported. Outside of randomized trials, remaining studies were likely to have tailored
patient treatment according to the clinical situation.
Results: Nine thousand four hundred and four DCIS cases in 9391 patients with 10-year follow-up were included.
The adjusted meta-regression LR rate for mastectomy was 2.6 % (95 % CI, 0.8–4.5); breast-conserving surgery
with radiotherapy (RT), 13.6 % (95 % CI, 9.8–17.4); breast-conserving surgery without RT, 25.5 % (95 % CI,
18.1–32.9); and biopsy-only (residual predominately low-grade DCIS following inadequate excision), 27.8 % (95 % CI,
8.4–47.1).
RT + tamoxifen (TAM) in conservation surgery (CS) patients resulted in lower LR compared to one or no adjuvant
treatments: LR rate for CS + RT + TAM, 9.7 %; CS + RT(no TAM), 14.1 %; CS + TAM(no RT), 24.7 %; CS(alone), 25.1 %
(linear trend for treatment P < 0.0001). Compared to CS + RT + TAM, a significantly higher invasive LR was observed for
CS(alone), odds ratio (OR) 2.61 (P < 0.0001); CS + TAM(no RT), OR 2.52 (P = 0.001); CS + RT(no TAM), OR 1.59 (P = 0.022).
BCDR was similar for mastectomy, breast-conserving surgery with or without RT (1.3–2.0 %) and non-significantly
higher for biopsy-only (2.7 %).
Additionally, the 15-year follow-up was reported where all like-studies had≥ 15-year data sets; the biopsy-only patients
had a meta-analysed total LR rate of 40.2 % and the invasive LR rate was 28.1 %. The biopsy-only patients had
a ≥ 15-year BCDR (that included women with metastatic disease) of 17.9 %; the ≥ 15-year BCDR was 55.2 % for
those with invasive LR.
Conclusions: More local intervention was associated with greater local control for patients with DCIS at long-term
follow-up. For patients undergoing breast-conservation, invasive LR was significantly lower when two rather than one
adjuvant treatment modalities were given.
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Background
Ductal carcinoma in situ (DCIS) of the breast is more
commonly diagnosed as a result of population-based
screening [1]. Various surgical and adjuvant treatments
have been extensively investigated for DCIS [2–6], but
less is known of long-term outcomes, as recurrence is
low, death infrequent and may occur years after the original
diagnosis [7, 8]. Our earlier meta-analysis yielded summary
ipsilateral local recurrence (LR)-rates of 22.5 % for breast-
conserving surgery (BCS), 8.9 % for BCS and radiotherapy
(RT), and 1.4 % for mastectomy (Mx), with average follow-
ups of 68, 62 and 80 months, respectively [2].
We performed a systematic review, meta-analysis and
meta-regression, focusing on studies with long-term out-
comes (≥10 years) for DCIS categorized by the extent of
local intervention ± tamoxifen (TAM) to assess LR and
breast cancer death. We aimed to highlight the natural
history of DCIS and guide patient management by deter-
mining treatment-related long-term outcomes.
Methods
This is a systematic review comprising study-level meta-
analysis and meta-regression segmented by treatment
modality.
Eligibility criteria
Published studies were systematically identified and
assessed for inclusion based on pre-defined eligibility
criteria: (1) all patients had pure DCIS, with no evidence
of invasion or nodal involvement; (2) had a minimum me-
dian or mean follow-up of 10 years, (3) provided descrip-
tions and proportions by surgery-type; (4) ipsilateral LR
(breast or chest wall) was a minimum reported outcome;
(5) outcome data (LR and breast cancer deaths) were doc-
umented in relation to surgery-type, and RT delivery for
BCS; and (6) minimum of five eligible patients per study
were reported.
Study selection and data collection
All published studies of any design were considered. No
language, publication date or study type restrictions were
imposed. On August 31 2013, studies were identified by
searching MEDLINE (OVID), Evidence-Based Medicine
Reviews databases and hand-searching of references.
The search strategy and Preferred Reporting Items for
Systematic Reviews and Meta-Analyses methodology are
online (Additional file 1). To ensure validity of follow-up
data, we sought results as closely related to 10 years
(minimum) as information in individual studies allowed
(Table 1). When there was more than one publication
from an institution or group, the latest study with longest
follow-up was used to extract 10-year data. Zero patient
overlap was an important goal for this analysis. Detailed
information on data inclusion methodology is reported
online (Additional file 2).
Our meta-analysis of recurrence- and death-rates by
treatment modality uses study-level data from four
prospective RCT trials [9–12], one prospective non-
randomized study [13], one study combining
prospective and retrospective data [14], and 20 retro-
spective studies [15–34].
Data items and endpoints
Information was extracted: (1) study information - number
of eligible patients, year published, main author, data-
accrual period, institutions involved, length of follow-up
and study type; (2) age of patients; (3) treatment modal-
ities - surgery-type, RT, systemic therapy; (4) outcomes
(LR and breast cancer deaths).
Primary clinical endpoints for meta-analysis were LR,
defined as subsequent ipsilateral breast or chest wall
(DCIS or invasive) disease, and breast cancer death rate
(BCDR), defined as number of deaths from breast cancer
divided by all eligible DCIS cases. The effect of adjuvant
therapy in the DCIS breast-conservation population was
examined. For treatment groups where all studies had
mean or median follow-up of ≥15 years (only the biopsy
group), further endpoints were examined: the 15-year
LR rate and the “≥15 year BCDR” (which included patients
with metastatic breast cancer).
Patients included in the biopsy-only group received
excision biopsies, with no attention to margins, as the
only treatment; these cases, with previously incorrect
diagnoses of benign breast disease, were identified as
DCIS on retrospective slide review [29–32]. Also, we
included data from two BCS trials that documented 3 %
of cases with micro-invasive disease: both reported on
repeat statistical analysis with the pure DCIS population,
and a difference in LR was not detected when com-
pared with the initial cohort [10, 11]. Reasons for exclu-
sion of some patients from eligible trials are outlined
online (Additional file 3). Margin analysis was not pos-
sible due to lack of margin-specific data.
Summary measures and statistical analysis
The 95 % confidence intervals (CIs) of LR and BCDR for
each individual study treatment-category of Mx, BCS
with RT (BCS + RT), BCS without RT (BCS) and biopsy-
only were calculated using exact binomial [35], or Poisson
[35] for zero numerators.
Meta-analysis combined same-treatment-categories to
produce pooled breast cancer-recurrence- and death-rates.
A random effects model used an exact likelihood method
in which within-study variance was based on binomial
distribution [36].
Odds ratios (OR) of LR within the four main treatment
groups (Mx, BCS + RT, BCS, biopsy-only) (Table 2), and
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Table 1 Characteristics of eligible studies and patients (n = 9404) in ductal carcinoma in situ meta-analysis
Patient age (years) Follow-up (years)
Study and publication year Collection of patient data Study design Country Mean or median Range Diagnosed at≤ 40 years (%) Number of eligible cases (Adjusted)a Mean or median Adjusteda
Betsill-1978 [32] 1940–1950 R US 48.2 34–59 20c 8 18f 10
Millis-1975 [19] 1948–1968 R UK 47 39–79 20 16 >15 10
Sanders-2005 [29] 1950–1968 R US 52b 33–80 25 25 31 10
Wanebo-1974 [23] 1953–1972 R US 53 22–86 NR 14 ≥10 10
Sunshine-1985 [17] 1960–1972 R US ABO NR 28d 85 >10 >10
Akashi-Tanaka-2000 [20] 1962–1995 R JP 47b 19–92 NR 13 13.4 10
Eusebi-1994 [30] 1964–1976 R IT 48.6 24–77 24 71 17.5f 10
Simpson-1992 [22] 1967–1977 R US NR NR NR 30 17.7f 10
Solin-1996 [27] 1967–1985 R EU/US 50 26–82 NR 270 10.3 10.3
Lagios-1989 [24] 1972–1980 R US 54 16–85 NR 20 10.3 10.3
Collins-2005 [31] 1973–1991 R US 55 39–63 7.7 13 17.4f 10
Lara-2003 [21] 1974–1992 R US 56 31–82 NR 73 19f 10
Tunon-de-Lara-2010 [18] 1974–2003 R FR 36.3 18–40 100 207 13.3 13.3
Di Saverio-2008 [25] 1976–2006 R IT ABO NR 8.5 186 10.8f 10.8
Ward-1992 [28] 1979–1983 R US 58.4b NR NR 11 >10f 10
Shaitelman-2012 [33] 1980–1993 R US NR NR 20.7 145 19.3 10
Ottesen-2000 [13] 1982–1989 P DK 48^ 29–85 NR 168 10 10
Holmes-2011 [34] 1983–2002 R US 55.5 NR 34e 141 10.2 10.2
Fisher-2001 [9] (B-17) 1985–1990 P + RCT US ABO NR NR 813 10.8 10.8
Vidali-2012 [16] 1985–2000 R IT 55 29–84 5.5 586 11.3 11.3
Bijker-2006 [10] 1986–1996 P + RCT EU 53 25–76 6.4 1010 10.5 10.5
Cuzick-2011 [11] 1990–1998 P + RCT UK/ANZ ABO NR 3.3d 1694 12.7 12.7
Owen-2013 [14] 1990–1999 P + R CA 55 27–92 8.6 637 12 12
Wapnir-2011 [12] (B-24) 1991–1994 P + RCT US 55 NR 17.3 1184 13.6 10
Rudloff-2009 [26] 1991–1995 R US 55 26–89 15.6d 91 11 11
Rakovitch-2013 [15] 1994–2003 R CA 56 20–85 12.4 1893 10 10
Abbreviations: R retrospective, P prospective, RCT randomized controlled trial, US United States, CA Canada, UK United Kingdom, JP Japan, IT Italy, EU Europe, FR France, DK Denmark, ANZ Australia and New Zealand,
ABO age bands only, NR not reported
aAs close as possible to 10 years from ≥10-year eligible data
bfor the DCIS patients in study
cIncluded all patients in study
d < 45 years












Table 2 Ipsilateral local recurrence and breast cancer death rates in ductal carcinoma in situ by four main treatment groups (Mastectomy, Breast-Conserving Surgery with or
without Radiation Therapy, and Biopsy-only) at ten years - meta-analysis and meta-regression
Meta-analysisa Meta-regressionb
Unadjusted Adjusted for weighted mean age & period, & 10-year follow-up
Treatment Groups DCIS cases Local recurrence or death Rate (%) & 95 % CI Model P heterog I2 heterogc Rate (%) & 95 % CI Rate (%) & 95 % CI Odds ratio P
All local recurrence
Model P-value P < 0.0001 P < 0.0001 P < 0.0001
Biopsy 4 117 28 35.8 R <0.001 83.6 29.8 27.8 14.15 <0.001
13.4–58.2 15.9–43.8 8.4–47.1 5.26–38.03
BCS 11 2605 653 25.2 R <0.001 86.7 23.9 25.5 12.59 <0.001
19.8–30.6 18.0–29.9 18.1–32.9 6.28–25.26
BCS + RT 13 5746 716 13.0 R <0.001 78.4 12.7 13.6 5.79 <0.001
10.9–15.1 9.6–15.8 9.8–17.4 2.90–11.55
Mastectomy 8 936 22 3.0 F = R ns 53.6 2.6 2.6 1.00
0.9–5.0 1.0–4.2 0.8–4.50 -
Total 36 9404 1419
Linear trend treatment P < 0.001 P < 0.001 P < 0.001
Invasive local recurrence
Model P-value P < 0.0001 P < 0.0001 P < 0.0001
Biopsy 4 117 21 26.6 R <0.01 77.1 21.0 10.9 6.83 <0.001
9.5–43.8 10.4–31.7 3.2–18.5 2.91–16.04
BCS 11 2601 290 11.0 R <0.01 64.7 10.6 10.7 6.72 <0.001
8.6–13.4 7.8–13.4 8.0–13.4 3.83–11.80
BCS + RT 10 5499 357 7.4 R <0.001 80.1 6.7 6.7 4.00 <0.001
5.2–9.5 5.1–8.4 5.4–8.0 2.26–7.08
Mastectomy 8 853 19 2.5 R <0.05 58.1 2.1 1.8 1.00
0.49–4.5 0.8–3.4 0.8–2.8
Total 33 9070 687
Linear trend treatment P < 0.001 P < 0.001 P < 0.001
Breast cancer deaths
Model P-value P = 0.3670 P = 0.1689 P = 0.1689
Biopsy 4 117 6 5.2 F = R ns 18.5 4.9 2.7 2.02 0.262
0.3–10.0 0.5–9.3 0.0–6.0 0.59–6.91











Table 2 Ipsilateral local recurrence and breast cancer death rates in ductal carcinoma in situ by four main treatment groups (Mastectomy, Breast-Conserving Surgery with or
without Radiation Therapy, and Biopsy-only) at ten years - meta-analysis and meta-regression (Continued)
1.9–3.2 1.4–3.3 0.9–3.1 0.75–3.02
BCS + RT 10 3751 83 2.4 R <0.001 73.0 2.2 1.9 1.41 0.319
1.5–3.4 1.5–2.9 1.2–2.6 0.72–2.77
Mastectomy 8 936 18 2 R ns 9.1 1.9 1.3 1.00
0.9–3.1 0.7–3.1 0.3–2.3 -
Total 31 7100 166
Linear trend treatment P = 0.2281 P = 0.0685 P = 0.0685
Abbreviations: DCIS ductal carcinoma in situ, CI confidence interval, BCS breast-conserving surgery, BCS + RT BCS + radiation therapy, F fixed effects, R random effects, ns non-significant. Odds ratio P-comparator
is mastectomy
aby variance weighting (Berry)
bby non-linear logistic regression of expanded data to unit records











also adjuvant treatments combinations (±RT,±TAM) in
the breast-conservation population (Table 3), were calcu-
lated for all treatment groups. Biopsy-only was comparator
in the four main treatment groups. BCS without adjuvant
treatment, CS(alone), was comparator in the analysis of
effect of adjuvant treatment in breast conservation patients.
Meta-regression was performed to assess and adjust
for effects of potential confounders for the following:
average age of women, period of initial treatment (as a
surrogate for timeframe-related treatment and detection
effects), follow-up duration for recurrence and death-
rates in each treatment group [37]. The models assessed
statistical significance, and adjusted recurrence- and
death-rates are provided.
Bias and confounding
Since this analysis is by treatment category at study-level
(aggregate) there may be issues of bias and confounding
related to differing study characteristics. A detailed dis-
cussion is online (Additional file 2).
Results
Study and treatment characteristics
Twenty-six studies, published between 1974 and 2013,
were eligible; 15 multi-institutional [9–18, 27–31] and the
remainder from single institutions [19–26, 32–34]. Four
studies were population-based [13–15, 28] (Table 1). A
total of 9404 DCIS cases in 9391 women with treated or
untreated DCIS (TisN0M0) between 1940 and 2006 are
included in this review by treatment type; 50.0 % of cases
(4701/9404) were from RCTs.
Eligible studies reported several surgical interventions for
DCIS: BCS (14 studies) [9–13, 15, 16, 24–28, 33, 34]; Mx
(4 studies) [14, 20, 22, 23]; both BCS and Mx (4 studies)
[17–19, 21]; and biopsy-only (4 studies) [29–32]. There
were 36 distinct groups of patients for analysis extracted
from the 26 studies, treated by Mx, BCS + RT (all cases
and ± TAM), BCS (all cases and ± TAM), or biopsy only,
with an average of 1.4 treatment types, hence treatment
groups, described per study.
DCIS cases were examined according to local treatment
received: Mx (936 cases) (10.0 %) [14, 17–23], BCS + RT
(5746 cases) (61.1 %) [9–12, 15, 16, 18, 26–28, 33], BCS
(2605 cases) (27.7 %) [9–11, 13, 17–19, 24, 25, 34], and
biopsy-only (117 cases) (1.2 %) [29–32]. Most patients
(88.8 %) in this analysis had BCS (of whom 68.8 % had
RT). The median reported whole-breast RT dose was
50 Gy; 7.1 % of the Mx population received RT.
Results of individual studies and of pooled analysis
Table 2 summarizes estimates of LR and BCDR by the
four main treatment groups (Mx, BCS + RT, BCS,
biopsy-only). The total (invasive and noninvasive) LR
rate for Mx was 2.6 %, BCS + RT 13.6 %, BCS 25.5 %
and biopsy-only 27.8 %, based on adjusted results from
the weighted mean age, period and 10-year follow-up
data in the meta-regression. Significant differences in
pooled LR-rates on meta-regression analysis were found
between Mx and BCS + RT, Mx and BCS, Mx and
biopsy-only, and between BCS and BCS + RT (all P <
0.0001). Significant differences were seen for invasive
LR-rates between Mx and each of the other treatments:
BCS + RT, BCS, and biopsy-only; and between BCS + RT
and BCS (all P < 0.0001). The magnitude of LR-rates for
each individual study, and the meta-analyzed summary
LR-rates (by treatment category), and their relationship
to each other are displayed in Figs. 1 and 2.
Table 3 summarizes estimates of LR and BCDR within
the breast conservation population. The addition of both
RT and TAM lessened the meta-regression rate of total
and invasive LR for patients with DCIS who had con-
servation surgery (CS), with the lowest total LR rate in
patients treated with CS + RT + TAM (9.7 %). Signifi-
cantly higher rates of total LR occurred in patients treated
with CS(alone), 25.1 %; CS + TAM(no RT) 24.7 %; and a
non-significantly higher rate was seen in CS + RT(no
TAM) 14.1 % (Table 3). A difference was identified
between the total LR-rates of CS + RT(no TAM) with
CS(alone) (P < 0.0001).
Significant differences were seen in the invasive LR
meta-regression rates between CS + RT + TAM (4.7 %)
and each of the other treatment types: CS(alone) 11.3 %,
CS + TAM(no RT) 11.0 %, CS + RT(no TAM) 7.2 %. Sig-
nificance was noted between the invasive LR OR of
CS(alone) compared with CS + RT(no TAM) or CS + RT +
TAM, (both P <0.0001), but not between CS(alone) and
CS + TAM(no RT) (Table 3).
The OR of LR was less with the addition of adjuvant
treatment on meta-regression. There was a significant
difference between the OR of CS + RT + TAM and the
adjuvant treatment groups (CS + TAM(no RT), OR = 3.05;
CS(alone),OR = 3.12) for total LR; similar results were
observed for invasive LR (CS +TAM(no RT),OR = 2.52;
CS(alone),OR = 2.61). Statistical significance was observed
for differences in invasive LR between CS + RT +TAM and
the adjuvant treatment CS + RT(no TAM) (OR = 1.59). A
trend for a higher invasive LR rate was demonstrated for
the CS + TAM(no RT) group compared to CS + RT(no
TAM) (OR = 1.59, CI 0.99–2.55; P = 0.055).
Meta-regression analysis of BCDR at 10 years was simi-
lar for the Mx, BCS + RT and BCS patients (1.3–2.0 %),
with overlapping 95%CIs. Although the biopsy-only group
had a higher BCDR of 2.7 %, this did not statistically differ
from estimates for the other three groups (Table 2). A
linear trend following the adjusted meta-regression was
noted for higher BCDR with less extensive treatment
(P = 0.0685) (Table 2), but no significance was observed
following the adjusted meta-regression for BCDR in
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Table 3 Ipsilateral local recurrence and breast cancer death rates in ductal carcinoma in situ breast conservation cases by adjuvant treatment (Conservation Surgery
Alone, Conservation Surgery with Radiation Therapy or Tamoxifen, and Conservation Surgery with both Radiation Therapy and Tamoxifen) at ten years - meta-analysis
and meta-regression
Meta-analysisa Meta-regressionb
Unadjusted Adjusted for weighted mean age & period, & 10-year follow-up
Treatment Groups DCIS cases Local recurrence or death Rate (%) & 95%CI Model P heterog I2 heterogc Rate (%) & 95 % CI Rate (%) & 95 % CI OR P
All local recurrence
Model P-value P = 0.0002 P = 0.0003 P = 0.0003
CS(alone) 10 2038 541 25.9 R <0.001 85.5 24.9 25.1 3.12 0.001
19.9–32.0 19.1–30.6 18.3–31.9 1.62–6.00
CS + TAM(no RT) 1 567 112 19.8 R <0.001 86.7 19.7 24.7 3.05 0.024
16.5-23.0 7.1–32.3 7.9–41.5 1.16–8.04
CS + RT(no TAM) 11 4809 630 14.9 R <0.001 78.4 13.8 14.1 1.52 0.190
11.8-18.0 10.6–16.9 10.3–17.8 0.81–2.86
CS + RT + TAM 2 937 86 9.2 F = R ns 53.6 8.5 9.7 1.00
7.3-11.0 3.9–13.2 4.4–15.0 -
Total 24 8351 1369
Linear trend treatment P < 0.001 P < 0.0001 P < 0.0001
Invasive local recurrence
Model P-value P = 0.0005 P < 0.0001 P < 0.0001
CS(alone) 10 2038 241 11.4 R <0.05 60.1 11.2 11.3 2.61 0.001
8.8–14.1 8.8–13.7 8.9–13.8 1.71–3.97
CS + TAM(no RT) 1 567 49 8.6 - - - 8.6 11.0 2.52 0.001
6.7–10.6 4.1–13.1 6.2–15.8 1.44–4.41
CS + RT(no TAM) 8 4562 317 7.7 R <0.001 79.0 7.4 7.2 1.59 0.022
5.9–9.5 5.8–8.9 6.1–8.3 1.07–2.35
CS + RT + TAM 2 937 40 4.3 F = R ns <0 4.1 4.7 1.00
3.0–5.6 2.2–6.0 3.0–6.4 -
Total 21 8104 647
Linear trend treatment P < 0.0001 P < 0.0001 P < 0.0001
Breast cancer deaths
Model P-value P = 0.6160 P = 0.4152 P = 0.4152
CS(alone) 8 1729 40 2.3 F = R ns <0 2.1 2.1 1.15 0.734











Table 3 Ipsilateral local recurrence and breast cancer death rates in ductal carcinoma in situ breast conservation cases by adjuvant treatment (Conservation Surgery
Alone, Conservation Surgery with Radiation Therapy or Tamoxifen, and Conservation Surgery with both Radiation Therapy and Tamoxifen) at ten years - meta-analysis
and meta-regression (Continued)
CS + TAM(no RT) 1 567 19 3.4 - - - 3.3 4.0 2.24 0.128
2.1–4.6 0.6–5.9 0.2–7.7 0.79–1.27
CS + RT(no TAM) 8 2814 67 2.7 R <0.001 76.4 2.3 2.2 1.21 0.613
1.4–3.9 1.5–3.2 1.2–3.1 0.58–2.54
CS + RT + TAM 2 937 16 1.7 R ns <0 1.6 1.8 1.00
0.9–2.5 0.5–2.8 0.6–3.0 -
Total 19 6047 142
Linear trend treatment P = 0.8591 P = 0.5586 P = 0.5586
Abbreviations: DCIS ductal carcinoma in situ, CI confidence interval, CS conserving surgery, CS + RT CS + radiation therapy, TAM tamoxifen, F fixed effects, R random effects, ns non-significant. Odds ratio P-comparator
is CS + RT + TAM
aby variance weighting (Berry)
bby non-linear logistic regression of expanded data to unit records











any of the combinations of adjuvant therapy compared
to patients treated with CS(alone) (Table 3).
Meta-regression adjusting for effects of average age,
period of treatment and follow-up duration for total LR
and invasive LR produced statistically significant models.
While recurrence-rates varied somewhat from the meta-
analysis, the relationship remained similar. There were
no evident effects of these variables on death-rates, with
all models non-significant.
The 15-year follow-up data of biopsy-only patients
was examined; the meta-analysed total LR rate was 40.2 %
(95 % CI, 17.0–63.4), and the invasive LR rate was
28.1 % (95 % CI, 11.7–44.6). The biopsy-only patients
had a ≥15 year BCDR of 17.9 % (95 % CI, 3.8–32.0);
the ≥15 year BCDR was 55.2 % (95 % CI, 37.1–73.3)
for those with invasive LR.
Discussion
This overview of long-term (≥10 years) outcomes of 9391
women with 9404 cases of DCIS confirms more extensive
local treatment is associated with lower rates of total
(DCIS or invasive) or invasive LR. This meta-analysis up-
dates and extends previous work [2], not only with longer
follow-up and more studies, but through the additional
evaluation of patients who had biopsy-only, adjuvant
TAM, and through meta-regression providing adjusted
estimates.
Fig. 1 Meta-analysis results: total (invasive and non-invasive) ipsilateral local recurrence rates at 10 years in cases of ductal carcinoma in situ
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Progressively lower estimated proportions of LR are
demonstrated with more treatment, from the least radical
local treatment (biopsy-only), with the highest LR rate
(27.8 %), through BCS (25.5 %) or BCS + RT (13.6 %), to
Mx with lowest LR (2.6 %). We found evidence of a reduc-
tion in ipsilateral LR (both invasive and DCIS) in those
receiving adjuvant RT ± TAM amongst BCS patients.
Those who have CS + RT + TAM demonstrate signifi-
cantly lower invasive LR-rates (4.7 %) than those who
receive CS(alone) and only one adjuvant treatment (TAM
11.0 %, RT 7.2 %).
This meta-analysis combines aggregate data from stud-
ies to estimate ipsilateral LR and BCDRs in patients with
DCIS with more precision than is possible in individual
studies. Combining studies increases cases for analysis
reducing stochastic variation. Confounding may occur
because of differences between studies in treatment cat-
egories with respect to age profile, period of diagnosis,
and country. Prospective studies are likely to have less
measurement bias than retrospective clinical cohort stud-
ies. RCTs often have stringent exclusion criteria and often
only include a minority of potential cases, whereas obser-
vational retrospective studies are more inclusive, providing
more generalizable results. Despite the outlined limita-
tions, summarizing published data using meta-analysis
may assist clinicians in estimating likely recurrence-rates
after various treatments. Outside of RCTs, the remaining
studies were likely to have tailored patient treatment
according to the clinical situation, with, for example, lar-
ger, higher-grade DCIS having more extensive surgery
such as a Mx rather than BCS with or without RT. Similar
outcomes between different treatment groups treated
according to risk does not prove that the treatments are
equivalent. This also applies to randomized trials where
selected patients with higher risk disease are not offered
participation in the trial.
Fig. 2 Meta-analysis results: invasive ipsilateral local recurrence rates at 10 years in cases of ductal carcinoma in situ
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Although this work is based on studies employing vari-
ous designs and follow-up durations, outcomes data were
approximated to 10 years to provide meaningful compari-
sons. In addition, we investigate outcomes at ≥ 15-years
follow-up in the biopsy-only group, finding high rates of
LR and breast cancer death; results should be interpreted
with knowledge these cases were only identified as having
DCIS on retrospective pathology review and may not be
entirely representative of outcomes for untreated DCIS.
Cases in the biopsy-only group were low-to-intermediate
grade DCIS left in situ, and help provide data on the nat-
ural history of this disease. Our study highlights even lon-
ger periods of follow-up may be necessary to detect
survival differences from local therapies, given the average
time to ipsilateral invasive breast cancer recurrence for
low-intermediate grade DCIS is 131 months and high
grade, 76-months [38]. The identified small difference in
LR between the biopsy-only and BCS groups could be
explained by the possibility positive margins remained
after the BCS surgery, the slow natural history of DCIS
and that there were only small numbers assessed in the
biopsy-only group. Also, DCIS may have been completely
excised in the biopsy-only specimens and been less
extensive.
Nine hundred and sixty-three DCIS patients treated by
Mx are identified with long-term outcomes reported at
10 years–the total LR rate was 2.6 %. This compares
with our earlier study with ≤ 10-year follow-up LR rate
of 1.4 % (0.7–2.1 %) [2]. Residual subcutaneous and
breast tissue containing tumor cells may have been left
in situ if suboptimal surgery had been performed, which,
in turn, may have raised the LR rate. As results are simi-
lar over the years of data collection (1953–2003), with
the exception of one paper with small numbers [20], it
would appear confounding from differing influences of
screening and treatment might not be as great as once
thought.
The addition of postoperative irradiation is advanta-
geous for local control for DCIS patients treated with
BCS, with adjuvant RT halving LR [2, 3]. Our early
meta-analysis recommended the addition of RT to BCS
to lower ipsilateral LR risk, particularly in tumors with
necrosis, high-grade cytological features, a comedo sub-
type, or close/positive surgical margins [2]. The DCIS
Oxford overview examined data from 3729 women man-
aged with BCS from four RCTs, two of which had 10-year
data available [3]. The absolute 10-year risk of any ipsilat-
eral event was reduced from 28 to 13 % with RT; women
aged over 50 years had the greatest proportional risk
reduction with RT. We include three of these trials in this
analysis; our results are in line with those of the Oxford
overview. Potentially, this absolute benefit of RT (with
minimal toxicity) added to BCS, may be even greater
when follow-up time is extended [39]. Long-term SEER
data revealed an equivalent left-to-right cardiac mortality
ratio when modern RT techniques were used [40, 41].
Scandinavian data detected the rate of major coronary
events was proportional to mean heart dose [42]; with
improved homogeneity of radiation dosing using 3D
and 4D computed tomography planning and intensity-
modulated radiation therapy, a decrease in late toxicity
is expected [43–45].
Our analysis highlights the effect of adjuvant treatment
in lessening total and invasive LR in BCS patients, com-
pared to no adjuvant treatment; those at lowest risk were
those who received both adjuvant treatments (RT and
TAM). Initial use of TAM in DCIS was sporadic, often
without knowledge of hormone receptor status.
The adjusted invasive LR rate in this review did not
appear to be lowered with the addition of TAM (CS(alone)
11.3 % versus CS + TAM(no RT) 11.0 %), whereas the
addition of RT to CS reduced invasive LR to 7.2 %, drop-
ping further to 4.7 % with CS + RT + TAM. It is puzzling
to understand why TAM did not seem to reduce the inva-
sive LR rate; Cuzick et al. reported significant rate reduc-
tions with TAM for ipsilateral LR of DCIS (hazard ratio
(HR) 0.71), and contralateral LR of invasive (HR 0.47) and
DCIS (HR 0.36), but TAM had no effect on ipsilateral
invasive LR rates (HR 0.95) [11]. The results suggest that
TAM does very little to prevent invasive recurrence on
the same side over and above CS alone. We know clinic-
ally that elderly patients with invasive breast cancer
treated with TAM rather than a mastectomy eventually
progress due to tumour resistance to this cytostatic drug
[46]. Given the long follow-up in our study, it is possible
any residual tumour cells would have become resistant.
On the other hand, the ipsilateral LR rate was reduced
when TAM was added to CS + RT. RT not only sterilizes
residual cancer cells within the breast, but could addition-
ally have a synergistic effect when combined with TAM;
whether this is due to post-RT factors within the altered
normal breast tissue, or is a weighting of effect of TAM in
the prevention of initiation of new cancer.
Wapnir et al. [12] observed an identical 7.5 % 15-year
cumulative invasive LR rate in patients with negative
margins ± TAM, but positive margins were predictive of
TAM response; TAM morbidity of endometrial cancer
risk at 163 months doubled in the CS + RT + TAM
group (1.7 %) when compared with the CS + RT(no
TAM) group (0.78 %) (P = NS). Recent articles estimate
DCIS has a mean estrogen receptor rate of 69–79 % and
discuss ER as a predictive biomarker for endocrine
manipulation [47–49]. A Cochrane review meta-analysis
examining the addition of TAM to RT for women with
breast conservation for DCIS demonstrated a lower risk
of ipsilateral (HR,0.75) and contralateral (HR,0.50) breast
events [50]. In two large TAM-RCTs, receptor status was
not used in the randomisation process, nor in reporting of
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outcomes [11, 12]. However, NSABP B-24 has since pub-
lished evidence of a significant reduction in subsequent
breast cancer with TAM use, only when tumor cells were
estrogen receptor positive, with no benefit identified in
estrogen receptor-negative tumors [51].
Invasive local control results suggesting that patients
receiving breast conservation for DCIS may benefit from
both RT +TAM must be considered in the context of the
risks and benefits of such therapies. Treatment should
ideally be discussed in a multidisciplinary forum and in-
clude an informed patient’s opinion and consent to validate
the final decision. Factors that may influence non-use of
TAM include: ER-negative DCIS, patients with a high risk
of subsequent complications such as deep venous
thrombosis, probability of menopausal symptoms and
endometrial cancer (especially age >65 years), particu-
larly when LR-risk is low. Factors in favor of TAM-use
may include presence of moderate-to-strong breast
cancer family history, significant surrounding atypical
hyperplasia or lobular carcinoma in situ, and the BCS +
RT patient’s perceived benefit of reducing 10-year risk
of invasive LR. The risk of metastatic breast cancer follow-
ing invasive recurrence from DCIS has been reported as
13–40 % [39, 52, 53]. Breast cancer-specific survival in
women diagnosed with DCIS is significantly reduced fol-
lowing an invasive LR; both Donker et al. and Wapnir et al.
documented respectively a 17-fold and 7-fold increase in
the risk of breast cancer death after an invasive LR com-
pared with those who had a DCIS LR or no LR [12, 53].
No significant difference in BCDR was observed at
10 years between the Mx, BCS + RT and BCS groups, pos-
sibly due to early detection and management of recur-
rences. The biopsy-only group had the highest BCDR at
10 years, and although not statistically different from
other groups, may be due to a small number of cases.
When ≥15-year follow-up data were used, the ≥15-year
BCDR in the biopsy-only group was high (17.9 %), poten-
tially a reflection of latent progression of invasive recur-
rences to metastatic disease and death. The 10-year
BCDRs were no different in patients who had CS ± adju-
vant therapy after meta-regression analysis. However, it
may be data are not yet mature enough to produce statis-
tical significance, considering the association between re-
duction in invasive LR and improvement in breast cancer
survival [54, 55]. The DCIS Oxford overview did not re-
port a breast cancer survival advantage, but only two of
four trials had long-term data [3].
In the NSABP B-17/B-24 studies, cumulative probabil-
ity of breast cancer-related death was 10.4 %, 10 years
after the occurrence of ipsilateral invasive breast cancer
recurrence [12]. In EORTC data, patients with ipsilateral
invasive LR had a significantly worse breast cancer-
specific survival at 60 % (HR,17.66) and overall survival
(HR,5.17) ten years after LR, compared to those who
had ipsilateral DCIS LR or did not experience a recur-
rence, with breast cancer-specific survival around
95 % (P < 0.001) highlighting that treatment strategy
minimizing invasive recurrence is important for some
patients [53].
Nomograms can estimate for risk recurrence for
women with DCIS. The Van Nuys Prognostic Index and
its variations (for Mx and BCS patients) has been evalu-
ated for risk recurrence in independent populations [56],
as has the Memorial Sloan-Kettering Cancer Center
(MSKCC) DCIS Nomogram (for BCS patients) [57]; the
MSKCC data were based on 1681 consecutive women.
Ongoing DCIS management trials include assessment
of the role of TAM versus aromatase inhibitors [58] and
of the role of trastuzumab in HER2-positive DCIS
patients [59]. A validation study of genetic profiling for
DCIS recurrence risk is under way [60]. These or other
approaches, alone or in combination, may provide an
outcome advantage over current management.
Conclusions
We systematically meta-analyzed DCIS case-data on LR
and the BCDR to provide comprehensive summary infor-
mation on long-term outcomes, accounting for study-level
potential confounders.
We have identified that more intensive local intervention
was significantly associated with greater local control for
patients with DCIS at long-term follow-up. For patients
undergoing breast-conservation, invasive LR was signifi-
cantly lower when two rather than one adjuvant treatment
modalities were given. Residual predominately low-grade
DCIS following inadequate excision (represented by the
biopsy-only group) resulted in high LR and BCDRs at
15 years.
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